• Inositec AG Appoints Dr Frits van Alphen as Chief Medical Officer

    Zurich, Switzerland, 18 January 2018 Inositec, a pioneer in the development of life-saving small molecule drugs based on inositol hexaphosphate (IP6), announced today the appointment of Frits van Alphen, MD, as Chief Medical Officer.

    Dr van Alphen has over 20 years of experience in clinical development and medical affairs, employed in roles of increasing responsibility. He has joined Inositec from Roche, where he headed the operational excellence team. He previously was Chief Medical Officer at Vifor Pharma, Head Medical Affairs Europe at Novartis as well as heading their Clinical Operations team in the Netherlands. Dr van Alphen has hands-on experience running Phase I to Phase IV studies across several therapeutic areas, including cardiovascular and metabolic diseases, and nephrology. As a physician, Dr van Alphen worked several years in anesthesiology and intensive care. Dr van Alphen earned his medical degree at Leiden University, the Netherlands.

    “As CMO at Inositec, I have the golden opportunity to utilize my broad experience and entrepreneurial mind-set to develop new medicines. These innovative products have the potential to significantly advance patient care in vascular and other calcification disorders, all with high unmet medical need,” said Dr van Alphen.

    “Dr van Alphen is a key addition to Inositec’s team as we enter IND/CTA-enabling studies with our lead program in the vascular calcification space and fine-tune our clinical strategy in view of first-in-human studies in 2019,” said CEO Dr Mattias Ivarsson.

    About Inositec

    Inositec is pioneering the development of life-saving small molecule drugs based on inositol phosphate, a natural facilitator of diverse cellular functions. Using its broadly applicable InosituneTM technology to adjust the chemical and physical properties of inositol phosphate analogs, Inositec is developing a novel class of drugs currently focusing on high-unmet medical needs related to calcification disorders. Inositec was founded in December 2015 based on the award-winning research of Dr Mattias Ivarsson, Prof Jean-Christophe Leroux and Prof Bastien Castagner at ETH Zurich, Switzerland. Further information can be found at www.inositec.com.

    Contacts:

    Inositec
    Mattias Ivarsson
    CEO and Co-Founder
    +41 44 271 07 55
    info@inositec.com

    Halsin Partners
    Mike Sinclair
    +44 (0)20 7318 2955
    msinclair@halsin.com

     

     

    Posted in Press Release | Leave a comment

    Inositec wins Swiss Technology Award 2017

    We are proud to have won the Swiss Technology Award 2017. More information here (German).

    Posted in News | Leave a comment

    Inositec featured in BioCentury

    BioCentury is featuring Inositec in this week’s emerging company profile. Read the article here (requires subscription).

    Posted in News | Leave a comment

    Interview of Inositec CEO by Scrip Intelligence

    Scrip Intelligence interviewed Mattias Ivarsson at BIO Europe 2016 in Cologne. The video can be found here.

    Posted in News | Leave a comment

    Inositec AG Secures CHF1.4 million in Seed Financing to Advance New Class of Inositol Hexaphosphate-Based Drug Candidates

    Lead programs address unmet medical needs in vascular calcification and C. difficile infection

    Zurich, Switzerland, 27th October 2016 – Inositec, a pioneer in the development of life-saving small molecule drugs based on inositol hexaphosphate (IP6), announced today the closing of a CHF1.4 million (US$1.42 million) seed financing. Investors participating in the round included VI Partners via the Venture Incubator fund and Zürcher Kantonalbank. The proceeds will be used to progress a drug candidate from Inositec’s proprietary Inositune platform through preclinical proof-of-concept.

    “Inositol hexaphosphate is a naturally occurring substance that acts as a messenger in cells and is involved in multiple biochemical pathways,” explained Dr. Mattias Ivarsson, CEO of Inositec. “Using this molecule as a starting point, we have created a new class of compounds that have been specifically designed to address various therapy areas. Our programs address significant medical needs in vascular calcification and Clostridium difficile infection. This financing will enable us to advance a lead candidate from one of these programs through preclinical evaluation and ready for progression to clinical studies.”

    In conjunction with the financing. Michael Wacker, PhD, was appointed as Chairman of the Board of Directors. Dr. Wacker is a serial entrepreneur, co-founding several companies including GlycoVaxyn and Limmatech. He also coaches start-ups in Switzerland for CTI, the governmental commission of technology and innovation.

    “Inositec has made tremendous progress since its founding in December last year. I have been very impressed by the broadly applicable technology as well as the dedicated manner in which the team is building the company,” stated Dr. Wacker. “Inositec’s compounds have significant promise in multiple therapeutic areas where there is a great need for new, effective medicines. I look forward to working alongside the management team to help deliver on this huge potential.”

    About Inositec

    Inositec is pioneering the development of life-saving small molecule drugs based on inositol phosphate, a natural facilitator of diverse cellular functions. Using its broadly applicable Inositune™ technology to adjust the chemical and physical properties of inositol phosphate analogs, Inositec is developing a novel class of drugs initially focusing on two areas of high-unmet medical need: calcification disorders and Clostridium difficile infection. Inositec was founded in December 2015 based on the award-winning research of Dr Mattias Ivarsson, Prof Jean-Christophe Leroux and Prof Bastien Castagner at ETH Zurich, Switzerland. Further information can be found at www.inositec.com.

    About VI Partners

    VI Partners is a Swiss venture capital firm and advisor to Venture Incubator (VI). VI was established by McKinsey & Company and the Swiss Federal Institute of Technology in Zürich (ETHZ) in 2001. VI is an evergreen fund with a paid in capital of CHF 101m. The investors are 10 Swiss blue-chip companies from industry and finance. For further information visit www.vipartners.ch.

    Contacts:

    Inositec
    Mattias Ivarsson
    CEO and Co-Founder Partner
    +41 44 271 07 55
    info@inositec.com

    Halsin Partners
    Mike Sinclair
    +44 (0)20 7318 2955
    msinclair@halsin.com

    Posted in Press Release | Leave a comment

    Inositec nominated for the 2016 deVigier prize

    Inositec has been short-listed together with 10 nominees for the deVigier prize. More info here.

    29th March 2016

    Posted in News | Leave a comment

    Inositec CEO named on Forbes 30 under 30 list

    Mattias Ivarsson appeared in the Science and Healthcare category of the 2016 Forbes 30 under 30 European list.

    1st March 2016

    Posted in News | Leave a comment

    Inositec CEO featured in ETH Globe magazine

    Mattias Ivarsson has a vision: he wants to keep a dangerous pathogen in check using an innovative approach. As a Pioneer Fellow, he is now taking his first steps on the path to making that vision a reality. Click here for the article (page 28)

    9th December 2015

    Posted in News | Leave a comment

    Inositec wins Winterthur Heuberger Young Entrepreneur Award

    Three Zurich-based start-ups were awarded this year’s Heuberger Winterthur Start-up Award. The three companies from the Life Sciences field each received CHF 150,000 in prize money. Three other start-ups were awarded CHF 50,000 each. Click here for an article and radio interview in German. Click here for an article in English.

    13th November 2015

    Posted in News | Leave a comment

    Inositec ranked 3rd in Switzerland’s premier business plan competition

    Check out the newsflash, the >>venture>> website or our video for more information.

    18th June 2015

    Posted in News | Leave a comment